Therefore, patients with HER2-rich and triple-negative subtype who exhibit marked tumor shrinkage in NAC but still have high levels of Ki67 might be good candidates for more aggressive adjuvant systemic treatments, such as extension of postoperative chemotherapy, proper radiotherapy, and administration of Capecitabine, which was recently shown to prolong the survival of non-pCR patients [31]. The gene discussed is ERBB2; the disease is neoplasm.